Side Effects of rosuvastatin: A Synthesis of Findings from 23 Studies

  1. Home
  2. Side Effects of rosuvastatin
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of rosuvastatin: A Synthesis of Findings from 23 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of rosuvastatin: A Synthesis of Findings from 23 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Rosuvastatin is a widely used statin drug for lowering cholesterol levels, but it can have side effects. 14 reported a case of photoexposed purpuric eruption mediated by rosuvastatin. 18 suggested that lawyer-submitted reports may have unintended consequences on safety signal detection in spontaneous adverse event reporting systems. 12 found that dietary cholesterol exacerbated statin-induced hepatic toxicity in Syrian Golden Hamsters and in patients in an observational cohort study. 13 reported a case of spontaneous development of immune-mediated necrotizing myopathy (IMNM) after chronic use of statins. 19 found that genetically guided statin therapy may have effects on statin perceptions, adherence, and cholesterol lowering. 15 evaluated the treatment of FH patients, the proportion of FH patients reaching low-density lipoprotein cholesterol (LDL-C) goals, and reasons for not reaching LDL-C goals. 22 examined the frequencies of ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups. 8 provided an updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. 1 discussed the rationale and design of a randomized, controlled SaveSAMS trial to evaluate the effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease. 9 reported a case where nutraceuticals reinforced drug side effects. 5 investigated the association of SLCO1B1 521T > C polymorphism with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients. 20 reviewed phyto-enrichment of yogurt to control hypercholesterolemia. 2 examined the possibility that statins may increase the risk of liver dysfunction in patients treated with steroids for active Graves' orbitopathy. 3 presented a case report of various abnormalities in lipid and glucose metabolism induced by capecitabine. 17 reviewed statins and male fertility. 23 discussed predictive modeling of HMG-CoA reductase inhibitory activity and design of new HMG-CoA reductase inhibitors. 6 investigated statin-roxadustat drug-drug-disease interaction using physiologically-based pharmacokinetic modeling. 4 explored directional drug interaction effects on myopathy using the FAERS database. 11 reported physicians' experiences as patients with statin side effects. 16 investigated the possibility that ribociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis. 7 examined the pharmacokinetic study of rosuvastatin in males and females. 10 proposed practical recommendations for clinical victim and perpetrator drug-drug interaction study design. 21 revealed that berberine promotes OATP1B1 expression and rosuvastatin uptake by inducing nuclear translocation of FXR and LXRα.

Reasons for Side Effects

Rosuvastatin side effects may be related to how the drug is metabolized in the body. 8 found that increased statin exposure is an important risk factor for skeletal muscle toxicity. Additionally, rosuvastatin side effects may be influenced by genetic factors. 22 showed that the frequency of ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups may impact the risk of statin-associated myopathy symptoms.

Common Side Effects

Muscle Pain

Statins can cause side effects such as muscle pain and weakness. 13 reported a case of spontaneous development of immune-mediated necrotizing myopathy (IMNM) after chronic use of statins. 5 investigated the association of SLCO1B1 521T>C polymorphism with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients. 16 investigated the possibility that ribociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis.

Hepatotoxicity

Statins can cause problems with the liver. 12 found that dietary cholesterol exacerbated statin-induced hepatic toxicity in Syrian Golden Hamsters and in patients in an observational cohort study. 2 examined the possibility that statins may increase the risk of liver dysfunction in patients treated with steroids for active Graves' orbitopathy.

Other Side Effects

Statins can cause a variety of side effects besides muscle pain and hepatotoxicity. 14 found that rosuvastatin caused photoexposed purpuric eruption. 9 reported a case where nutraceuticals reinforced drug side effects.

Measures for Side Effects

Muscle Pain

If you experience muscle pain from statins, consult your doctor. They can recommend appropriate measures such as reducing the dosage of statins or switching to a different medication.

Hepatotoxicity

To prevent hepatotoxicity caused by statins, it is important to get regular blood tests to monitor liver function.

Other Side Effects

If you experience other side effects from statins, consult your doctor.

Comparison between Studies

Similarities in Studies

These studies show that rosuvastatin can cause side effects such as muscle pain and hepatotoxicity. They also suggest that rosuvastatin side effects may be influenced by genetic factors and environmental factors such as diet.

Differences in Studies

These studies differ in a variety of aspects such as the incidence and severity of side effects, the types of side effects, etc.

Points to Note for Applying the Research to Real Life

It is important to understand the risks of side effects when taking rosuvastatin. If you experience any side effects such as muscle pain or liver abnormalities while taking rosuvastatin, consult your doctor immediately.

Limitations of Current Research

There is not enough research on the side effects of rosuvastatin. More research is needed.

Future Research Directions

To better understand the side effects of rosuvastatin, the following research is needed: * Research to clarify the mechanisms that cause rosuvastatin side effects * Research to identify risk factors for rosuvastatin side effects * Research to develop new methods to prevent or treat rosuvastatin side effects

Conclusion

Rosuvastatin is an effective drug for lowering cholesterol levels, but it can rarely cause side effects such as muscle pain and hepatotoxicity. It is important to understand the risks of side effects when taking rosuvastatin. If you experience any side effects such as muscle pain or liver abnormalities while taking rosuvastatin, consult your doctor immediately.

Literature analysis of 23 papers
Positive Content
14
Neutral Content
2
Negative Content
6
Article Type
1
0
0
4
20
1.

Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial.

Author: ChaJung-Joon, HongSoon Jun, KimJu Hyeon, LimSubin, JooHyung Joon, ParkJae Hyoung, YuCheol Woong, LeePil Hyung, LeeSeung Whan, LeeCheol Whan, MoonJae Youn, LeeJong-Young, KimJung-Sun, ParkJae Suk, LeeKyounghoon, LimSang Yup, NaJin Oh, ChoJin-Man, KimSeok Yeon, LimDo-Sun

LDL-C reduction
Elderly risk
Muscle symptoms

This study discusses the challenges of maintaining statin use in elderly patients with established atherosclerotic cardiovascular disease (ASCVD) despite current guidelines recommending high-intensity statin therapy. The study highlights the reluctance to maintain statin use due to side effects, particularly statin-associated muscle symptoms (SAMS), and the lack of randomized trials on the safety of statin therapy in elderly patients.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.

Author: CovelliDanila, VannucchiGuia, CampiIrene, CurròNicola, D'AmbrosioRoberta, MaggioniMarco, GianelliUmberto, Beck-PeccozPaolo, SalviMario

Graves' Orbitopathy Treatment
Liver Toxicity

Intravenous glucocorticoids are used to treat Graves' orbitopathy, a condition that affects the muscles and tissues around the eyes. High doses of intravenous glucocorticoids can cause liver damage. The study found that patients with Graves' orbitopathy who are also taking statins, a type of cholesterol-lowering drug, should be carefully monitored for liver problems.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Case Report: Various Abnormalities in Lipid and Glucose Metabolism Induced by Capecitabine.

Author: AnnoTakatoshi, YamatsujiTomoki, TomodaKoichi, NakanishiShuhei, KanetoHideaki

Hypertriglyceridemia

Capecitabine, a chemotherapy drug, can cause dyslipidemia, including hypertriglyceridemia. This case report describes a patient with sigmoid colon cancer who developed dyslipidemia during capecitabine treatment, which was effectively managed with rosuvastatin.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

5.

SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.

Author: LiuJu-E, LiuXiao-Ying, ChenSheng, ZhangYan, CaiLi-Yun, YangMin, LaiWei-Hua, RenBin, ZhongShi-Long

Statin myotoxicity risk

SLCO1B1 (rs4149056, 521T>C) is associated with statin-induced myotoxicity in Chinese patients with coronary artery disease. This genetic variant also increased the risk of rosuvastatin-associated myotoxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling.

Author: DongJin, Prieto GarciaLuna, HuangYingbo, TangWeifeng, LundahlAnna, ElebringMarie, AhlströmChristine, VildhedeAnna, SjögrenErik, NågårdMats

CKD management
Drug-drug interaction
Side effects

This study used physiologically-based pharmacokinetic (PBPK) modeling to understand the impact of severe chronic kidney disease on statin pharmacokinetics and drug-drug interactions. PBPK models were used to predict statin-roxadustat DDI risks in patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Pharmacokinetic study of rosuvastatin in males and females.

Author: NazirShabnam, IqbalZafar, ShahYasar, AhmadLateef, KhanAbad

Dyslipidemia treatment
Cardiac myopathy

Rosuvastatin levels are significantly higher in women than men, which could be a possible reason for higher incidence of cardiac myopathy and other side effects in women.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins.

Author: HirotaTakeshi, FujitaYuito, IeiriIchiro

Hypercholesterolemia treatment
Skeletal muscle toxicity

This abstract provides information about statins, a class of drugs used to lower cholesterol levels. It discusses the different mechanisms by which various statins are metabolized and transported in the body, highlighting the potential for drug interactions and muscle toxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

When Nutraceuticals Reinforce Drugs Side Effects: A Case Report.

Author: RussoRoberto, GallelliLuca, CannataroRoberto, PerriMariarita, CalignanoAntonio, CitraroRita, RussoEmilio, GareriPietro, CorsonelloAndrea, SarroGiovambattista De

Improved lipid disorders
Drug interactions
Muscle injury

Nutraceutical approaches are becoming increasingly popular for managing lipid and metabolic disorders, particularly due to the side effects of statins.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

10.

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Author: LeeCaroline A, O'ConnorMeeghan A, RitchieTasha K, GaletinAleksandra, CookJack A, Ragueneau-MajlessiIsabelle, EllensHarma, FengBo, TaubMitchell E, PaineMary F, PolliJoseph W, WareJoseph A, Zamek-GliszczynskiMaciej J

Drug efficacy and safety
Drug-drug interactions

This review discusses the challenges and proposes strategies for conducting clinical drug-drug interaction (DDI) studies that are mediated by breast cancer resistance protein (BCRP). BCRP is a transporter protein involved in drug absorption and excretion. The review recommends specific substrates (sulfasalazine, rosuvastatin) and inhibitors (curcumin, lapatinib) for clinical DDI studies and suggests study design considerations to assess the worst-case scenario.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Dietary Cholesterol Exacerbates Statin-Induced Hepatic Toxicity in Syrian Golden Hamsters and in Patients in an Observational Cohort Study.

Author: YuQiongyang, MaXiurui, WangYunan, ShiHaozhe, AnJian, WangYuhui, DongZhen, LuYijing, GeJunbo, LiuGeorge, XianXunde, SunAijun

Liver toxicity
Muscle toxicity

Statins are commonly prescribed for lowering cholesterol, but can cause muscle and liver toxicity. This study explores the use of hamsters as a model system to study the hepatotoxicity of statins, due to their metabolic similarities to humans.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

14.

Rosuvastatin induced photolocalized purpura.

Author: ThaboutiMarwa, Gahriani FetouiNadia, ManaaLinda, RouatbiJacem, SrihaBadreddine, Ben SalemChaker, DenguezliMohamed

Skin eruption

This study describes a case of photoexposed purpuric eruption mediated by rosuvastatin, a rare cutaneous side effect of statins.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.

Author: VohnoutBranislav, FábryováĽubomíra, KlabníkAlexander, KadurováMichaela, BálinthKarin, KozárováMiriam, BugáňováIngrid, SirotiakováJana, RašlováKatarína

LDL-C management

This retrospective study evaluated the treatment of FH patients in Slovakia and found that a significant proportion of patients were either under-treated or not treated at all. The study also evaluated the proportion of FH patients reaching LDL-C goals and the reasons for not reaching these goals.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

16.

Ribociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis.

Author: TeoSiaw Wee, HayesTheresa, GomeJames

Acute kidney injury
Rhabdomyolysis

This case report describes a woman with metastatic hormone receptor positive breast cancer who developed rhabdomyolysis and acute kidney injury while on a combination therapy of ribociclib and rosuvastatin. The report highlights the potential risk of rhabdomyolysis associated with this drug combination and underscores the importance of continued vigilance for this side effect, even after long-term therapy.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Statins and Male Fertility: Is There a Cause for Concern?

Author: OmolaoyeTemidayo S, HalabiMouhammad Omar, MubarakMaitha, CyrilAsha Caroline, DuvuruRuthwik, RadhakrishnanRajan, Du PlessisStefan S

Anti-inflammatory effects
Cardioprotective effects
Altered semen parameters
Erectile dysfunction
Modified steroid hormone production
Testicular discomfort

This review explores the contradictory findings on the effects of statins on male sexual health and reproductive parameters. While some studies suggest negative effects on fertility due to altered steroid hormone production, others suggest potential benefits from statins' anti-inflammatory properties.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.

Author: RogersJames R, SarpatwariAmeet, DesaiRishi J, BohnJustin M, KhanNazleen F, KesselheimAaron S, FischerMichael A, GagneJoshua J, ConnollyJohn G

Improved signal detection
Not applicable

Lawyer-submitted reports did not significantly distort known safety signals for isotretinoin and atorvastatin in the US FDA Adverse Event Reporting System (FAERS). The inclusion of these reports did not meaningfully impact the detection of safety signals for other adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Phyto-Enrichment of Yogurt to Control Hypercholesterolemia: A Functional Approach.

Author: KumarHarsh, BhardwajKanchan, Cruz-MartinsNatália, SharmaRuchi, SiddiquiShahida Anusha, DhanjalDaljeet Singh, SinghReena, ChopraChirag, DantasAdriana, VermaRachna, DosokyNoura S, KumarDinesh

HC management
Yogurt consumption benefits
HC complications

This review discusses the benefits of yogurt consumption for managing hypercholesterolemia (HC). While yogurt has a rich nutritional value, its processing can reduce the content of beneficial constituents. The review highlights the potential of phyto-enriched yogurt as a healthy and effective alternative to conventional treatment approaches for HC.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.